Literature DB >> 2494913

Immunologic, histopathologic, and bacteriologic responses of five strains of mice to Brucella abortus strain 2308.

G W Pugh1, E S Zehr, V P Meador, M Phillips, T J McDonald, B L Deyoe.   

Abstract

A study was conducted to establish baseline data on Brucella abortus infection induced in 5 strains of mice (CBA/NJ, BALB/c, CD-1, C3H/HeN, and C3H/HeJ). The strains were compared on the basis of immunologic, histopathologic, and bacteriologic responses. There were 4 treatment groups for each strain of mice: (1) vaccinated with homologous lipopolysaccharide and challenge exposed to B abortus strain 2308; (2) not vaccinated but challenge exposed; (3) vaccinated and not challenge exposed; and (4) not vaccinated and not challenge exposed. Results indicated that mice can be used for comparative studies on the pathogenesis and immunogenesis of B abortus infections; strains of mice may vary in their responses to Brucella infection, regardless of their vaccination status. Bacteriologic and immunologic responses in mouse strains BALB/c, CD-1, C3H/HeN, and C3H/HeJ, but not those of CBA/NJ, were extrapolative among strains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494913

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  10 in total

1.  The Brucella melitensis M5-90 phosphoglucomutase (PGM) mutant is attenuated and confers protection against wild-type challenge in BALB/c mice.

Authors:  Yu Zhang; Tiansen Li; Jing Zhang; Zhiqiang Li; Yan Zhang; Zhen Wang; Hanping Feng; Yuanzhi Wang; Chuangfu Chen; Hui Zhang
Journal:  World J Microbiol Biotechnol       Date:  2016-02-29       Impact factor: 3.312

2.  Lymphocyte proliferation in response to Brucella abortus 2308 or RB51 antigens in mice infected with strain 2308, RB51, or 19.

Authors:  M G Stevens; S C Olsen; G W Pugh
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

3.  Construction of Cu-Zn superoxide dismutase deletion mutants of Brucella abortus: analysis of survival in vitro in epithelial and phagocytic cells and in vivo in mice.

Authors:  F M Tatum; P G Detilleux; J M Sacks; S M Halling
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Deletion of purE attenuates Brucella melitensis infection in mice.

Authors:  R M Crawford; L Van De Verg; L Yuan; T L Hadfield; R L Warren; E S Drazek; H H Houng; C Hammack; K Sasala; T Polsinelli; J Thompson; D L Hoover
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

5.  Impaired control of Brucella melitensis infection in Rag1-deficient mice.

Authors:  M J Izadjoo; Y Polotsky; M G Mense; A K Bhattacharjee; C M Paranavitana; T L Hadfield; D L Hoover
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

6.  Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308.

Authors:  M G Stevens; S C Olsen; G W Pugh; M V Palmer
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Deletion of the BCSP31 gene of Brucella abortus by replacement.

Authors:  S M Halling; P G Detilleux; F M Tatum; B A Judge; J E Mayfield
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Variation of Brucella abortus 2308 infection in BALB/c mice induced by prior vaccination with salt-extractable periplasmic proteins from Brucella abortus 19.

Authors:  G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

Review 9.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

10.  Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection.

Authors:  Elías Barquero-Calvo; Esteban Chaves-Olarte; David S Weiss; Caterina Guzmán-Verri; Carlos Chacón-Díaz; Alexandra Rucavado; Ignacio Moriyón; Edgardo Moreno
Journal:  PLoS One       Date:  2007-07-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.